Invesco Ltd. Tango Therapeutics, Inc. Transaction History

Invesco Ltd.

$516 Billion
Q4 2024

A detailed history of Invesco Ltd. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 29,534 shares of TNGX stock, worth $71,767. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,534

Previous 28,950 2.02%

Holding current value

$71,767

Previous $222,000 59.01%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$2.79 - $7.46 $1,629 - $4,356	584 Added 2.02%	29,534 $91,000
Q3 2024 Nov 12, 2024	BUY	$7.36 - $11.93 $3,805 - $6,167	517 Added 1.82%	28,950 $222,000
Q2 2024 Aug 13, 2024	BUY	$6.66 - $10.15 $2,524 - $3,846	379 Added 1.35%	28,433 $243,000
Q1 2024 May 14, 2024	SELL	$7.51 - $12.88 $3.3 Million - $5.66 Million	-439,199 Reduced 94.0%	28,054 $222,000
Q4 2023 Feb 12, 2024	SELL	$6.52 - $12.01 $2 Million - $3.69 Million	-307,485 Reduced 39.69%	467,253 $4.63 Million
Q3 2023 Nov 13, 2023	BUY	$2.93 - $11.26 $2.2 Million - $8.46 Million	751,593 Added 3247.32%	774,738 $8.72 Million
Q2 2023 Aug 11, 2023	SELL	$2.67 - $4.7 $2,296 - $4,042	-860 Reduced 3.58%	23,145 $76,000
Q1 2023 May 12, 2023	SELL	$3.76 - $8.06 $711,685 - $1.53 Million	-189,278 Reduced 88.75%	24,005 $94,000
Q4 2022 Feb 13, 2023	BUY	$3.41 - $8.29 $647,736 - $1.57 Million	189,952 Added 814.16%	213,283 $1.55 Million
Q3 2022 Nov 14, 2022	SELL	$3.25 - $5.46 $117 - $196	-36 Reduced 0.15%	23,331 $85,000
Q2 2022 Aug 15, 2022	BUY	$3.86 - $8.01 $90,196 - $187,169	23,367 New	23,367 $105,000

Others Institutions Holding TNGX

# of Institutions

137

Shares Held

91.1M

Call Options Held

1.4K

Put Options Held

4.4K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $214M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account